|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma显示文摘瞄准:学习的目的是与食道的癌(LASCOC ) 与权威的 chemoradiotherapy (CRT ) 对待的局部地先进的有鳞的房间在病人评估幸存的预兆的因素政体基于 5FU/CDDP 联合。方法:有用在 1994 和 2000 之间的 5FU/CDDP 联合与权威的 CRT 对待的 LASCOC 的所有病人回顾地被包括。对 CRT 的临床的完全的反应(CCR ) 被食道的内视镜检查法和 CT 扫描估计在 CRT 结束以后的 2 瞬间。幸存的预示的因素用 univariate 被估计,多,由艇长回归的变量分析当模特儿。结果:116 个病人的一个总数在学习被包括。到 CRT 的 CCR 在 86/116 (74.1%) 被观察。中部的幸存是 20 瞬间(范围 2-114 ) , 5 年的幸存是 9.4% 。到 CRT 的应答者病人的中部的幸存在非应答者病人作为与 9 瞬间(范围 2-81 ) 相比是 25 瞬间(范围 3-114 )(P <
0.001 ) 。在 univariate 分析,幸存与 CCR 被联系(P <
0.001 ) ,表演地位 <
2 (P = 0.01 ) ,瘤长度 <
6 厘米(P = 0.045 ) 并且 10% 在意义的限制的重量损失 <
(P = 0.053 ) 。在里面多变量分析,幸存对 CCR 依赖(P <
0.0001 ) ,重量损失 <
10%(P = 0.034 ) 并且表演 <
2 (P = 0.046 ) 。结论:我们的结果建议在有与权威的 CRT 对待的 LASCOC 的病人的那幸存被相关到 CCR,重量损失并且表演地位。 | Frédéric Di Fiore Stéphane Lecleire Olivier Rigal Marie-Pierre Galais Emmanuel Ben Soussan Isabelle David Bernard Paillot Jacques-Henri Jacob Pierre Michel | 2006 | World Journal of Gastroenterology2006，12，26： | 13 |
| 2 | Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study显示文摘 | Conmy T Paillot B Francois E | 2005 | J Clin Oneol2005，23，6： | 1 |
| 3 | Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer显示文摘 | H Bleiberg T Conroy B Paillot A.J Lacave G Blijham J.H Jacob L Bedenne M Namer P De Besi F Gay L Collette T Sahmoud | 1997 | European Journal of Cancer1997，，8： | 1 |
| 4 | Obsessive compulsive disorder in a patient with twiddler' s syndrome 显示文摘 | Jaafari N Bachollet MS Paillot C | 2009 | Pacing Clin Electrophysiol2009，32，3： | 1 |
| 5 | Antibody and IFN-γresponses induced by a recombinant canarypox vaccine and challenge infection with equine influenza virus显示文摘 | PAILLOT R KYDD J H SINDLE T | 2006 | Vet Immunol Immunopathol2006，112，34： | 1 |
| 6 | Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer 显示文摘 | Bleiberg H Conroy T Paillot B | 1997 | Eur J Cancer1997，33，8： | 1 |
| 7 | Ramdomized phase Stuay of cisplatin and 5-Fu versus cisplatin alone in advanced spuamous cell esophageal cancer and metastatic gastric cancer显示文摘 | Conroy T Paillot B | 1997 | Eur J cancer1997，33，7： | 1 |
| 8 | Multicenter non-randomized phase Ⅱ study of raltitrexed ( Tomudex ) and oxaliplatin in non-pretreated metastatic colorectal cancer patients 显示文摘 | Seitz JF Bennouna J Paillot B | 2002 | Ann Oncol2002，13，7： | 1 |
| 9 | Abdominal radiotherapy is a cause for chronic pancreatitis显示文摘 | Lévy P Menzelxhiu A Paillot B | | 0，，03： | 1 |
| 10 | Randomized phase II study ofcisplatin and 5-fluorouracil(5-FU) versus cisplatin alone in advancedsquamous cell oesophageal cancer显示文摘 | Bleiberg H Conroy T Paillot B | 1997 | Eur JCancer1997，33，8： | 1 |
| 11 | Randomised phase Ⅱ study of cisplatin and 5 fluorouracil versus cisplatin alone in anvanced squamous cell oesophageal cancer显示文摘 | Bleiberg H Conroy T Paillot B | 1997 | Eur J Cancer1997，33，8： | 1 |
| 12 | The value of preoperative radiotherapy in esophageal cancer: Results of astudy by the EORTC显示文摘 | Gignoux M Roussel A Paillot B | 1987 | World J Surg1987，11，4： | 1 |
| 13 | Raltitrexed (Tomudex ? ) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1)显示文摘 | Ivan Popov Alfredo Carrato Alberto Sobrero Mark Vincent David Kerr Roberto Labianca Angelo Raffaele Bianco Mostafa El-Serafi Laurent Bedenne Bernard Paillot Enrico Mini Evaristo Sanches John Welch Laurence Collette Michel Praet Jacques Wils | 2008 | European Journal of Cancer2008，，15： | 1 |
| 14 | 5-Flourouracil ( 5-Fu )continuous intravenous infusion compared with blous adminisrtaion:final results of a randomized trial in metastatic colorectal cancer显示文摘 | Rougier PH Paillot B LaPlanche A | 1997 | Eur J Cancer1997，33，11： | 1 |
| 15 | Irinotecan plus oxaliplatin fluorouracil in advanced pancreatic cancer-a groupe tumeurs digestives of the federation nationale des centres de lutte contre le cancer study显示文摘 | Conroy T Paillot B Francois E | 2005 | J Clin Oncol2005，23，6： | 1 |
| 16 | Genomic evidence for the evolution of Streptococcus equi:host restriction,increased virulence,and genetic exchange with human pathogens显示文摘 | Holden MTG Heather Z Paillot R | | 0，，03： | 1 |
| 17 | Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer-a Groupe Tumeurs Digestives of the Federation Nationale des Centres de LuRe Contre le Cancer study显示文摘 | Conroy T Paillot B Francois E | | 0，，： | 1 |
| 18 | The value of preoperative radiotherapy in esophageal cancer: results of a study by the EORTC 显示文摘 | Roussel A Paillot B | 1988 | Recent Results Cancer Res1988，110，： | 1 |
| 19 | Fas independependent apoptosis ofactivated T cells induced by antibodies to HLA class I domain显示文摘 | Genestier L Paillot R Bonnefoy-Berard N | 1997 | Blood1997，90，： | 1 |
| 20 | Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer显示文摘 | H Bleiberg T Conroy B Paillot A.J Lacave G Blijham J.H Jacob L Bedenne M Namer P De Besi F Gay L Collette T Sahmoud | 1997 | European Journal of Cancer1997，，8： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员